There is no shame in holding at a dose that works
Distant Future: The patents on the active ingredient for popular medications like semaglutide are not expected to expire for several years
Based on the current status of the Phase 3 TRIUMPH program, Eli Lilly is expected to file a New Drug Application (NDA) in late 2026
The most common side effects mirror those of injectable GLP-1s nausea, mild digestive discomfort, reduced appetite, and occasional headaches, particularly in the first few weeks
The most common issues are gastrointestinal, including nausea, vomiting, or delayed stomach emptying (gastroparesis)
Do not assume a dose change automatically changes the price, and do not assume it never does